Company Overview - Averin Capital Acquisition Corp. is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily focusing on opportunities in the technology and health industries [2]. IPO Details - The company announced the pricing of its initial public offering (IPO) of 25,000,000 units at a price of $10.00 per unit, with units expected to be listed on the Nasdaq Global Market under the ticker symbol "ACAAU" starting February 19, 2026 [1]. - Each unit consists of one Class A ordinary share and one-sixth of one redeemable warrant, with each whole warrant allowing the holder to purchase one Class A ordinary share at a price of $11.50 per share [1]. - An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering, which is expected to close on February 20, 2026, subject to customary closing conditions [1]. - The underwriters have been granted a 45-day option to purchase up to an additional 3,750,000 units at the initial public offering price to cover over-allotments [1]. Management Team - The management team is led by David A. Berry as Chairman and Chief Executive Officer, and Alex Lau as Chief Financial Officer and Secretary. The Board of Directors includes Ulrik Schulze, Graeme Bell, and Mary T. Szela [3]. Underwriting - Deutsche Bank Securities Inc. is acting as the sole book-running manager for the offering [3]. Regulatory Information - A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on February 18, 2026 [5]. - The offering is being made only by means of a prospectus, which can be obtained from Deutsche Bank Securities Inc. or accessed via the SEC's website [4].

Core Insights - Nu Skin Enterprises reported fourth quarter and full-year 2025 results within guidance, achieving over 50% growth in earnings for the year [1] - The company anticipates a return to revenue growth by the end of 2026, driven by the global launch of Prysm iO intelligent wellness devices [1] Financial Performance - Q4 2025 revenue was $370.3 million, a decrease of 16.9% year-over-year, or 10.4% excluding Mavely revenue [1] - Full-year 2025 revenue totaled $1.49 billion, down 14.3% from 2024, or 10.7% excluding Mavely revenue [1] - Earnings per share (EPS) for Q4 2025 was $0.29, compared to a loss of $(0.73) in Q4 2024, or $0.38 excluding restructuring and other charges [1] - Full-year EPS for 2025 was $3.18, compared to $(2.95) in 2024, or $1.27 excluding Mavely gain and other charges [1] Customer and Affiliate Metrics - The total number of customers decreased by 10% to 748,796 in Q4 2025 compared to the previous year [1] - Paid affiliates decreased by 11% to 129,311, while sales leaders fell by 19% to 30,045 [1] Segment Performance - Revenue by region for Q4 2025 showed declines across all major markets, with the Americas down 9.8%, Southeast Asia/Pacific down 22.7%, and Mainland China down 7.8% [3] - For the full year 2025, revenue in the Americas decreased by 12.3%, Southeast Asia/Pacific by 14.3%, and Mainland China by 16.9% [3] Outlook for 2026 - Q1 2026 revenue is projected to be between $320 million and $340 million, reflecting a decline of 12% to 7% [1] - Full-year 2026 revenue is expected to range from $1.35 billion to $1.50 billion, with an EPS forecast of $0.80 to $1.20 [1] Strategic Initiatives - The company is focusing on aligning sales leaders around the launch of Prysm iO, with over 20,000 devices already distributed [1] - Pre-market activities in India are underway, with a full market opening anticipated in the latter half of 2026 [1]

Core Insights - Tenet Healthcare Corporation reported strong financial results for the fourth quarter and full year 2025, with a net income of $371 million or $4.22 per diluted share in Q4 2025, reflecting a 16.7% increase from Q4 2024 [1][2] - Adjusted diluted earnings per share rose 36.6% to $4.70 in Q4 2025 compared to $3.44 in Q4 2024, driven by robust revenue growth and disciplined expense management [1][2] - The company anticipates FY 2026 Adjusted EBITDA to be between $4.485 billion and $4.785 billion, indicating continued growth expectations [1][2] Financial Performance - Q4 2025 net operating revenues reached $5.527 billion, up 8.9% from $5.073 billion in Q4 2024, while FY 2025 revenues totaled $21.310 billion, a 3.1% increase from $20.675 billion in FY 2024 [1][5] - Consolidated Adjusted EBITDA for Q4 2025 was $1.183 billion, a 12.9% increase from $1.048 billion in Q4 2024, with an Adjusted EBITDA margin of 21.4% [1][2] - The company generated free cash flow of $2.53 billion in FY 2025, compared to $1.116 billion in FY 2024, highlighting improved cash generation capabilities [1][5] Segment Performance - The Ambulatory Care segment reported Q4 2025 net operating revenues of $1.433 billion, a 13.8% increase from $1.259 billion in Q4 2024, driven by strong same-facility net patient service revenues [2][6] - The Hospital Operations segment saw Q4 2025 net operating revenues of $4.094 billion, a 7.3% increase from $3.814 billion in Q4 2024, attributed to favorable payer mix and higher acuity services [2][6] - Adjusted EBITDA for the Ambulatory segment was $580 million in Q4 2025, up 9.4% from $530 million in Q4 2024, while the Hospital segment's Adjusted EBITDA increased to $603 million from $518 million in the same period [2][6] Balance Sheet and Cash Flow - Cash flows from operating activities for FY 2025 were $3.54 billion, significantly higher than $2.047 billion in FY 2024, reflecting improved operational efficiency [1][5] - The company repurchased 8.8 million shares for $1.386 billion in FY 2025, indicating a commitment to returning value to shareholders [1][5] - As of December 31, 2025, the ratio of net debt to Adjusted EBITDA was 2.25x, down from 2.54x a year earlier, indicating improved leverage [1][5] 2026 Financial Outlook - For FY 2026, Tenet expects net operating revenues to be between $21.500 billion and $22.300 billion, with net income available to common stockholders projected between $2.605 billion and $2.840 billion [2][6] - The company anticipates Adjusted EBITDA margins to range from 20.9% to 21.5% in FY 2026, reflecting continued operational improvements [2][6] - The Ambulatory segment is expected to see net operating revenues of $5.500 billion to $5.700 billion, while the Hospital segment is projected to generate $16.000 billion to $16.600 billion in revenues [2][6]

Core Viewpoint - dsm-firmenich has agreed to divest its Animal Nutrition & Health (ANH) business to CVC Capital Partners for an enterprise value of approximately €2.2 billion, which includes an earnout of up to €0.5 billion, while retaining a 20% equity stake in the divested companies [1][2]. Group 1: Transaction Details - The divestment of ANH follows the sale of Feed Enzymes activities to Novonesis for €1.5 billion in 2025, marking a strategic shift for dsm-firmenich to focus solely on consumer sectors in nutrition, health, and beauty [2]. - The total enterprise value of ANH, including the previous sale, amounts to €3.7 billion, reflecting a 10x EV/Adjusted EBITDA multiple [2][5]. - dsm-firmenich expects to receive approximately €1.2 billion post-transaction, with an estimated €0.6 billion in net cash proceeds and a vendor loan note of €0.1 billion [5][12]. Group 2: Business Structure and Operations - ANH will be divided into two standalone companies: the "Solutions Company" and the "Essential Products Company," both based in Kaiseraugst, Switzerland [5]. - The Solutions Company will focus on Performance Solutions, Premix, and Precision Services, while the Essential Products Company will handle Vitamins, Carotenoids, and Aroma Ingredients [5]. - dsm-firmenich will enter into a long-term supply agreement for vitamins with the Essential Products Company to ensure continuity in supply for human and pet food applications [5]. Group 3: Financial and Strategic Implications - The transaction is expected to result in a non-cash impairment of around €1.9 billion in 2025 before taxes, with additional cash tax and transaction costs of €0.2 billion anticipated in 2026 [12]. - dsm-firmenich plans to initiate a share repurchase program worth €0.5 billion in Q1 2026 and aims to maintain a stable dividend of €2.50 per share, with a policy of progressively increasing dividends over time [3][4]. - The CEO of dsm-firmenich emphasized that this divestment represents the final step in their strategic roadmap, aiming to accelerate growth and create long-term value for stakeholders [7].

Core Insights - Tmall International is set to welcome 2,415 new overseas brands in 2025, indicating a double-digit growth in the number of first stores opened, averaging over 6 new brands daily [1][3] - The top three new imported brands for 2025 include the South Korean fashion brand COVERNAT, the Australian nutrition brand herbs of gold, and the South Korean celebrity merchandise brand Weverse Shop [1][3] - The new brands span 52 countries and regions, with the highest number coming from the United States, Japan, and South Korea, while France, New Zealand, and Australia show the fastest growth [1][3] Industry Trends - The most concentrated influx of new overseas brands is in the health, beauty, and maternal and infant sectors, with the maternal and infant industry seeing a 128% increase in new brands, particularly in the baby food segment [1][3] - The fastest-growing categories in terms of transaction volume over the past year include toys, outdoor equipment, baby food, fashion cosmetics, and pet health, all of which have doubled in growth, reflecting consumer preferences for quality imports and family-oriented products [1][3] Brand Expansion - Tmall International currently hosts over 40,000 brands from more than 110 countries and regions, indicating a significant global reach and brand diversity [2][4]

Fertility startup Inito wants to use AI-designed antibodies to expand at-home health tests https://t.co/03debIl0nO ...

Core Points - The U.S. Department of the Treasury and the IRS issued guidance allowing more workers to benefit from "no tax on tips" and "no tax on overtime" provisions under President Trump's legislation [1] - The 2025 budget reconciliation bill permits workers to deduct up to $25,000 in tips and $12,500 in overtime from their income, with exemptions for certain specified service trades [2] - Additional guidance is deemed necessary to help determine if an employer's business qualifies as a specified service trade [3] Summary by Sections - **Transition Relief**: The guidance provides "transition relief" until January 1 of the first calendar year after final rules are issued, recognizing that many small businesses have not previously made such determinations [4] - **Penalty Relief**: Employers are granted penalty relief for tax year 2025 regarding the provision of correct information on qualified tips and overtime compensation [4] - **Tax Forms Update**: The IRS has not updated tax forms for 2025 and encourages employers to provide tipped employees with occupation codes and separate accounting of cash tips [5] - **Implementation Preparation**: Employers should prepare for the implementation of these provisions, despite the easing of the law [6] - **Reporting Requirements**: Employers are advised to provide employees with reports detailing cash tips, qualifying occupations, and qualified overtime compensation, especially for accurate calculations in tax year 2026 [7]

Core Insights - SBC Medical Group Holdings reported a revenue decrease of 18% year-over-year for Q3 2025, primarily due to restructuring initiatives and a revised fee structure for clinic services [3][5][8] - Despite the revenue decline, the company saw significant improvements in profitability, with net profit rising by 353% year-over-year, driven by lower operating expenses [4][6][8] - The company aims to pursue sustainable growth by focusing on high-quality solutions and expanding its multi-brand initiatives in dermatology [5][12] Q3 2025 Financial Results - Total revenues for Q3 2025 were $43 million, an 18% decrease from the previous year [5][8] - Income from operations increased by 15% year-over-year to $16 million [4][8] - Net income attributable to SBC Medical Group was $13 million, compared to $3 million in Q3 2024 [6][8] - EBITDA for the quarter was $17 million, reflecting a 12% increase, with an EBITDA margin of 38% [7][8][21] - The number of franchise locations increased to 258, up by 34 from the previous year, and the customer count reached 6.5 million, a 14% year-over-year increase [8][9] Year-to-Date 2025 Highlights - For the nine months ended September 30, 2025, total revenues were $134 million, a 17% decrease year-over-year [9] - Net income for the nine-month period was $37 million, down 8% from the previous year [9] - EBITDA for the nine months was $57 million, also a 17% decrease, with an EBITDA margin of 42% [9][21] Future Outlook - The company plans to continue its focus on delivering high-quality solutions and expanding its presence in overseas markets, particularly in dermatology [5][12]

Core Insights - Full Alliance Group, Inc. reported a strong third-quarter performance with significant achievements across its business segments [1] Group 1: Contract Manufacturing - Aquaox Pure Solutions achieved record contract manufacturing volume with over 155,000 units secured this quarter, indicating a substantial increase in demand from health, beauty, and wellness industry partners [1] Group 2: Consumer Brand Launch - The company successfully launched its doctor-endorsed consumer brand JUSSPRAY™ on Amazon, marking a significant entry into the consumer market [1] Group 3: International Expansion - Full Alliance Group secured its first international agricultural contract, highlighting its growth and expansion into new markets [1]

Core Insights - XWELL, Inc. has launched a redesigned digital platform that integrates its full brand ecosystem, enhancing user experience for customers, investors, and job seekers [1][2][3] Group 1: Digital Platform Features - The updated website unites XWELL's health, wellness, and beauty brands, including Xpres Spa, Naples Wax Center, XpresCheck, and HyperPointe™, providing a cohesive user experience [2] - Key features of the new website include simplified appointment booking, enhanced investor relations page, careers page refresh, dynamic announcement tools, and mobile optimization [7] Group 2: Company Vision and Strategy - The launch of the new website reflects XWELL's vision to redefine wellness engagement, making it more seamless and personalized for users [3] - The company is rebranding its flagship Xpres Spa locations to align under the XWELL name, reinforcing its mission to unify its offerings under a wellness-forward identity [4][5] Group 3: Brand Identity and Engagement - The new platform incorporates updated logos and color palettes, visually representing the brand's evolution [7] - XWELL has also enhanced its social media presence, particularly on Instagram, to engage with customers more effectively [4]